Submission of Earnings Call Transcript for the call held on 05.08.2026

Date: 11th August 2026 National Stock Exchange of India Limited BSE Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Bandra Kurla Dalal Street, Mumbai – 400001 Complex, Bandra (E), Mumbai – 400051 Scrip Code: 544619 Scrip Symbol- SUDEEPPHRM Sub: Q1 & FY 2026-27 Earnings Call Transcript Ref: Regulation 30 of the SEBI Listing Regulations, 2015 Dear Sir/Ma’am, We refer to our previous letter dated 5th August 2026, wherein the Company updated the audio link of Earnings call held on 5th August 2026 to discuss the operational & financial performance of the Company for the quarter ended on 30th June 2026. In context therein, kindly find attached herewith transcript of the referred Earnings call. A copy of the same is also available on the Company’s website at https://www.sudeeppharma.com/investor-relations/financial-results/#concall-transcript Kindly take the same on record. Thanking You. For Sudeep Pharma Limited Dimple Mehta Company Secretary & Compliance Officer M. No.: F13184 ENCL: A/a CIN: L24231GJ1989PLC013141 Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India. Phone No.: +91 265 2840656, 7624095107 Corporate Office: 601, 602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021, Gujarat, India Website: www.sudeepgroup.com, Email ID: mail@sudeepgroup.com “Sudeep Pharma Limited Q1 FY27 Earnings Conference Call” August 05, 2026 “E&OE - This transcript is edited for factual errors and readability. In case of discrepancy, the audio recordings uploaded on the stock exchange on 05th August 2026 will prevail.” MANAGEMENT: MR. SUJIT BHAYANI -- MANAGING DIRECTOR – SUDEEP PHARMA LIMITED MR. SHANIL BHAYANI – DIRECTOR – SUDEEP PHARMA LIMITED MR. KETAN VYAS – CHIEF FINANCIAL OFFICER – SUDEEP PHARMA LIMITED MODERATOR: MR. ARCHIT JOSHI -- NUVAMA INSTITUTIONAL EQUITIES Page 1 of 18 Sudeep Pharma Limited August 05, 2026 Moderator: Operator: Ladies and gentlemen, good day, and welcome to the Sudeep Pharma Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing '*' then '0' on your touchtone phone. Please note, this conference is being recorded. I now hand the conference over to Mr. Archit Joshi from Nuvama Institutional Equities. Thank you, and over to you, sir. Archit Joshi: Thank you. Good morning, everyone. On behalf of Nuvama Institutional Equities, I welcome you all on Sudeep Pharma's 1Q FY27 earnings conference call. We have with us from the management today, Mr. Sujit Bhayani, Managing Director; Mr. Shanil Bhayani, Director; and Mr. Ketan Vyas, Chief Financial Officer, to initiate the proceedings. I hand over the call to the management for their opening remarks, post which we can take a Q&A session. Thank you, and over to you, sir. Sujit Bhayani: Thank you, Archit, and good morning, everyone. I am Sujit Bhayani, here. First of all, I'd like to thank the Nuvama team for hosting today's earnings conference call. On behalf of the entire Sudeep Pharma team, I'd like to extend a warm welcome and thank you all for joining us for this Q1 FY27 earnings conference call. Q1 FY27 marks a strong and resilient start to the new financial year. We delivered revenue growth of 27% year-on-year, driven by broad-based performance across both our pharma, food and nutrition and specialty ingredient business. This performance was achieved despite a challenging global operating environment characterized by geopolitical uncertainties, intermittent gas supply constraints, elevated logistics costs and continued supply chain disruption. Over the past several quarters, we have remained focused on improving operational efficiencies through manufacturing excellence initiatives and manpower optimization. These efforts have helped us mitigate cost pressures, improve operational leverage and support our overall business performance during the quarter. We are also delighted to welcome Mr. Milin Mehta to our Board of Directors. Mr. Mehta brings with him extensive experience in business strategy, finance, and corporate governance. We are confident that his guidance and insight will further strengthen our leadership team and support the company as we enter the next phase of our growth journey. On behalf of the entire Sudeep Pharma family, I extend a warm welcome to him and look forward to his valuable contribution. Before I conclude, I'd like to highlight that our diversified product portfolio, strong global customer relationships, and balanced geographic presence continue to provide resilience in our evolving global environment. Supported by our ongoing growth initiatives and disciplined execution, we remain confident in our ability to sustain our long-term growth trajectory and create enduring value for our stakeholders. Page 2 of 18 Sudeep Pharma Limited August 05, 2026 With this, I would like to now hand over the call to Shanil, who will take you through the business and operational highlights in greater detail. Thank you, and over to Shanil. Shanil Bhayani: Good morning, and a very warm welcome to all of you joining us today. I hope you have had the opportunity to review our financial results and investor presentation, which have been uploaded on the stock exchanges, as well as our website. For today's call, I would like to focus on three areas: the key drivers behind our performance this quarter, the progress across our strategic growth initiatives, and our outlook for the remainder of the year. We are pleased to report a quarter of strong growth with consolidated revenue growing 27% year-on-year. This growth was predominantly driven by our operations in India, and I would like to emphasize this because it reflects the quality and resilience of the growth we are delivering. Our overseas subsidiary, NSS, had a more challenging quarter, operating in a difficult European environment. However, we believe this to be temporary in nature and the underlying momentum in our core businesses remain robust, supported by healthy customer demand, an improving product mix, and the investments we have made over the past several years in expanding our commercial capabilities and international presence. The quarter was not without its challenges. Continued logistics disruptions, elevated freight costs, and a sharp increase in sulfur prices resulted in phosphoric acid price increasing by approximately 50% during the quarter. Despite these headwinds, we remained focused on protecting customer relationships, ensuring continuity of supply, and effectively passing on the price increase, which will largely offset the input cost impact in Q2. Looking at the business today, we are encouraged by the underlying fundamentals. Demand remains healthy across our key product categories, our custom pipeline continues to strengthen, our specialty portfolio is gaining increasing market acceptance, and the strategic investments we have made over the past few years are beginning to translate into stronger operating performance. We, therefore, believe the business is well-positioned for another year of profitable growth. Our pharma, food and nutrition business remained our largest business segment and started the year with a strong quarter with revenues growing 31% year-on-year. Demand across both our phosphate and Absorbis Bisglycinates portfolios remain robust. In particular, customer demand for our phosphate portfolio continues to exceed our current manufacturing capacity, providing us with excellent visibility for the balance of the financial year and reinforcing our confidence in the sustainability of this growth. Our Absorbis Bisglycinates portfolio also continues to exceed our expectations. Sales during the first quarter have already surpassed the total sales achieved during the entire previous financial year, reflecti [Showing first 8,000 characters — download PDF for full document]